ZIOPHARM Oncology (NASDAQ:ZIOP) received a $6.50 price objective from equities research analysts at Raymond James in a research report issued on Tuesday, BayStreet.CA reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Raymond James’ price target points to a potential upside of 34.30% from the company’s previous close.

Several other equities analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $6.50 price objective on shares of ZIOPHARM Oncology in a report on Tuesday. ValuEngine lowered ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 2nd. BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, October 29th. Finally, Zacks Investment Research lowered ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. ZIOPHARM Oncology has an average rating of “Hold” and a consensus price target of $6.65.

Shares of ZIOP stock opened at $4.84 on Tuesday. The stock’s 50-day moving average is $4.65 and its two-hundred day moving average is $4.95. The firm has a market cap of $876.19 million, a price-to-earnings ratio of -10.08 and a beta of 2.60. ZIOPHARM Oncology has a 1 year low of $1.56 and a 1 year high of $7.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.34 and a current ratio of 10.34.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.34). As a group, research analysts predict that ZIOPHARM Oncology will post -0.33 EPS for the current year.

In other news, CAO Kevin G. Lafond sold 11,667 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $5.25, for a total transaction of $61,251.75. Following the completion of the sale, the chief accounting officer now owns 97,222 shares in the company, valued at $510,415.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.00% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC boosted its stake in shares of ZIOPHARM Oncology by 32.5% during the second quarter. Steward Partners Investment Advisory LLC now owns 25,427 shares of the biotechnology company’s stock worth $148,000 after buying an additional 6,240 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of ZIOPHARM Oncology by 10.8% during the third quarter. Janney Montgomery Scott LLC now owns 100,701 shares of the biotechnology company’s stock worth $431,000 after buying an additional 9,787 shares during the period. Vanguard Group Inc. boosted its stake in shares of ZIOPHARM Oncology by 11.6% during the second quarter. Vanguard Group Inc. now owns 11,254,728 shares of the biotechnology company’s stock worth $65,615,000 after buying an additional 1,167,963 shares during the period. Swiss National Bank boosted its stake in shares of ZIOPHARM Oncology by 11.7% during the second quarter. Swiss National Bank now owns 254,820 shares of the biotechnology company’s stock worth $1,486,000 after buying an additional 26,600 shares during the period. Finally, Morgan Stanley boosted its stake in shares of ZIOPHARM Oncology by 13.2% during the second quarter. Morgan Stanley now owns 1,385,120 shares of the biotechnology company’s stock worth $8,075,000 after buying an additional 161,833 shares during the period. Institutional investors and hedge funds own 45.63% of the company’s stock.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Featured Story: What is the S&P/TSX Index?

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.